CD8A and hepatocellular carcinoma: In vitro restimulation experiments and in vivo depletion studies have shown that both CD4+ and CD8+ cells contribute to antitumor activity. Using PBMC from healthy volunteers and patients with HCC, it was shown that ASPH stimulation led to significant development of antigen-specific CD4+ T cells.